Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis

F. R. Rosendaal, M. Vessey, A. Rumley, E. Daly, M. Woodward, F. M. Helmerhorst, G. D O Lowe

Research output: Contribution to journalArticle

Abstract

Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities. Therefore, we determined the two most common prothrombotic mutations, factor V Leiden and prothrombin 20210A in women who participated in a case-control study on venous thrombosis. Relative risks were expressed as odds ratios (OR) with 95% confidence intervals (CI95). Among 77 women aged 45-64 years with a first venous thrombosis, 51% were receiving HRT at the time of thrombosis, compared with 24% of control women (OR = 3.3, CI95 1.8-5.8). Among the patients, 23% had a prothrombotic defect, versus 7% among the control women (OR = 3.8, CI95 1.7-8.5). Women who had factor V Leiden and used HRT had a 15-fold increased risk (OR = 15.5, CI95 3.1-77), which exceeded the expected joint odds ratio of 6.1 (under an additive model). We conclude that the thrombotic risk of HRT may particularly affect women with prothrombotic mutations. Efforts to avoid HRT in women with increased risk of thrombosis are advisable.

Original languageEnglish (US)
Pages (from-to)851-854
Number of pages4
JournalBritish Journal of Haematology
Volume116
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Venous Thrombosis
Hormone Replacement Therapy
Odds Ratio
Mutation
Therapeutics
Thrombosis
Prothrombin
Case-Control Studies
Joints
Confidence Intervals

Keywords

  • Factor V Leiden
  • Hormone replacement therapy
  • Oestrogens
  • Prothrombin 20210A
  • Venous thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Rosendaal, F. R., Vessey, M., Rumley, A., Daly, E., Woodward, M., Helmerhorst, F. M., & Lowe, G. D. O. (2002). Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. British Journal of Haematology, 116(4), 851-854. https://doi.org/10.1046/j.0007-1048.2002.03356.x

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. / Rosendaal, F. R.; Vessey, M.; Rumley, A.; Daly, E.; Woodward, M.; Helmerhorst, F. M.; Lowe, G. D O.

In: British Journal of Haematology, Vol. 116, No. 4, 2002, p. 851-854.

Research output: Contribution to journalArticle

Rosendaal, FR, Vessey, M, Rumley, A, Daly, E, Woodward, M, Helmerhorst, FM & Lowe, GDO 2002, 'Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis', British Journal of Haematology, vol. 116, no. 4, pp. 851-854. https://doi.org/10.1046/j.0007-1048.2002.03356.x
Rosendaal, F. R. ; Vessey, M. ; Rumley, A. ; Daly, E. ; Woodward, M. ; Helmerhorst, F. M. ; Lowe, G. D O. / Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. In: British Journal of Haematology. 2002 ; Vol. 116, No. 4. pp. 851-854.
@article{ac20153084514f35afa29f9c71978d1f,
title = "Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis",
abstract = "Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities. Therefore, we determined the two most common prothrombotic mutations, factor V Leiden and prothrombin 20210A in women who participated in a case-control study on venous thrombosis. Relative risks were expressed as odds ratios (OR) with 95{\%} confidence intervals (CI95). Among 77 women aged 45-64 years with a first venous thrombosis, 51{\%} were receiving HRT at the time of thrombosis, compared with 24{\%} of control women (OR = 3.3, CI95 1.8-5.8). Among the patients, 23{\%} had a prothrombotic defect, versus 7{\%} among the control women (OR = 3.8, CI95 1.7-8.5). Women who had factor V Leiden and used HRT had a 15-fold increased risk (OR = 15.5, CI95 3.1-77), which exceeded the expected joint odds ratio of 6.1 (under an additive model). We conclude that the thrombotic risk of HRT may particularly affect women with prothrombotic mutations. Efforts to avoid HRT in women with increased risk of thrombosis are advisable.",
keywords = "Factor V Leiden, Hormone replacement therapy, Oestrogens, Prothrombin 20210A, Venous thrombosis",
author = "Rosendaal, {F. R.} and M. Vessey and A. Rumley and E. Daly and M. Woodward and Helmerhorst, {F. M.} and Lowe, {G. D O}",
year = "2002",
doi = "10.1046/j.0007-1048.2002.03356.x",
language = "English (US)",
volume = "116",
pages = "851--854",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis

AU - Rosendaal, F. R.

AU - Vessey, M.

AU - Rumley, A.

AU - Daly, E.

AU - Woodward, M.

AU - Helmerhorst, F. M.

AU - Lowe, G. D O

PY - 2002

Y1 - 2002

N2 - Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities. Therefore, we determined the two most common prothrombotic mutations, factor V Leiden and prothrombin 20210A in women who participated in a case-control study on venous thrombosis. Relative risks were expressed as odds ratios (OR) with 95% confidence intervals (CI95). Among 77 women aged 45-64 years with a first venous thrombosis, 51% were receiving HRT at the time of thrombosis, compared with 24% of control women (OR = 3.3, CI95 1.8-5.8). Among the patients, 23% had a prothrombotic defect, versus 7% among the control women (OR = 3.8, CI95 1.7-8.5). Women who had factor V Leiden and used HRT had a 15-fold increased risk (OR = 15.5, CI95 3.1-77), which exceeded the expected joint odds ratio of 6.1 (under an additive model). We conclude that the thrombotic risk of HRT may particularly affect women with prothrombotic mutations. Efforts to avoid HRT in women with increased risk of thrombosis are advisable.

AB - Hormone replacement therapy (HRT) increases the risk of venous thrombosis. We investigated whether this risk is affected by carriership of hereditary prothrombotic abnormalities. Therefore, we determined the two most common prothrombotic mutations, factor V Leiden and prothrombin 20210A in women who participated in a case-control study on venous thrombosis. Relative risks were expressed as odds ratios (OR) with 95% confidence intervals (CI95). Among 77 women aged 45-64 years with a first venous thrombosis, 51% were receiving HRT at the time of thrombosis, compared with 24% of control women (OR = 3.3, CI95 1.8-5.8). Among the patients, 23% had a prothrombotic defect, versus 7% among the control women (OR = 3.8, CI95 1.7-8.5). Women who had factor V Leiden and used HRT had a 15-fold increased risk (OR = 15.5, CI95 3.1-77), which exceeded the expected joint odds ratio of 6.1 (under an additive model). We conclude that the thrombotic risk of HRT may particularly affect women with prothrombotic mutations. Efforts to avoid HRT in women with increased risk of thrombosis are advisable.

KW - Factor V Leiden

KW - Hormone replacement therapy

KW - Oestrogens

KW - Prothrombin 20210A

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0036125032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036125032&partnerID=8YFLogxK

U2 - 10.1046/j.0007-1048.2002.03356.x

DO - 10.1046/j.0007-1048.2002.03356.x

M3 - Article

C2 - 11886391

AN - SCOPUS:0036125032

VL - 116

SP - 851

EP - 854

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -